• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Predictive Technology Group Acquires Regenerative Medical Technologies, Inc.

Share:

October 22, 2018

Predictive Technology Group, Inc., a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that it has acquired Regenerative Medical Technologies, Inc. The acquisition includes an allogeneic stem cell product design, intellectual property, access to data and medical records from patients in 13 clinics, and clinical trial methodology for degenerative disc disease.

Concurrent with the acquisition of RMT, Rick Obray, M.D. joins as Chairman of the Predictive Clinical Advisory Board. Dr. Obray received his Doctor of Medicine degree from Johns Hopkins University School of Medicine. After completing a spine and musculoskeletal fellowship at Johns Hopkins, Dr. Obray completed an interventional pain fellowship at Mayo Clinic, making him one of the few physicians in the country to complete fellowship training and receive board certifications in both pain medicine and diagnostic imaging. Dr. Obray also currently serves as the director of Spine and Pain Medicine at Intermountain Health Care’s Dixie Regional Medical Center.

“We are pleased to complete the RMT acquisition and welcome Dr. Obray to the Predicitive team as we expand our clinical expertise and further advance Predictive’s DDD development platform,” said Bradley Robinson, CEO of Predictive Technology Group. “With his expertise and clinical experience, Dr. Obray provides insight into the latest in spinal care and treatment, clinical research, and real world perspective to multidisciplinary care for patients. As translational medicine is a highly interdisciplinary field, Dr. Obray’s experience brings tremendous value to Predictive in addressing both patient needs for new and more effective precision therapies while addressing concerns of all stake holders in healthcare.”

Dr. Obray stated, “It has been my longtime ambition to provide relief to patients through revolutionary approaches utilizing precision medicine. I am very excited to join the Predictive team in bringing disruptive technology and new treatment options to those suffering from degenerative disc disease.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Date: October 22, 2018

Source: Yahoo Finance

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Gimv and other Shareholders Sell Biopharmaceutical Company Breath Therapeutics to Zambon after a Fast DevelopmentGimv and other Shareholders Sell Biopharmaceutical Company Breath Therapeutics to Zambon after a Fast Development
  • Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of CancerTherapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer
  • Global Aminobenzoic Acid Market Key Manufactures, Insights and Industry Trends Analyzed till Period, 2026Global Aminobenzoic Acid Market Key Manufactures, Insights and Industry Trends Analyzed till Period, 2026
  • Ensuring A Healthy Approach to Big Data In The Life Sciences IndustryEnsuring A Healthy Approach to Big Data In The Life Sciences Industry
  • Google Rolls Out Health Equity Tracker Platform, Highlighting Disparities Between CommunitiesGoogle Rolls Out Health Equity Tracker Platform, Highlighting Disparities Between Communities
  • Key Considerations for Veeva Vault ImplementationKey Considerations for Veeva Vault Implementation
  • DrChrono EHR, Cognition IP Partner to Process 5 Machine Learning-based PatentsDrChrono EHR, Cognition IP Partner to Process 5 Machine Learning-based Patents
  • Smart Wearables to Unlock the Next Level of Precision MedicineSmart Wearables to Unlock the Next Level of Precision Medicine

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications